Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Rappta Therapeutics","sponsor":"Novo Seeds","pharmaFlowCategory":"D","amount":"$10.6 million","upfrontCash":"Undisclosed","newsHeadline":"Novo Seeds Co-Leads Rappta Therapeutics Series A Financing for the Development of Phosphatase 2A Drugs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"FINLAND","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Rappta Therapeutics

    Menu

    Rappta Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Rappta Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Finland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Novo Seeds Co-Leads Rappta Therapeutics Series A Financing for the Development of Phosphatase 2A Drugs

              Details:

              Rappta has developed proprietary tools and a unique understanding of PP2A which allows it to therapeutically reactivate PP2A.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Novo Seeds

              Deal Size: $10.6 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing October 13, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY